Expanding Ambulatory Monitoring After TAVI May Prevent Serious Events

Why It Matters

Systematic post‑TAVI monitoring can markedly lower life‑threatening events while remaining cost‑effective, prompting potential updates to clinical guidelines.

Key Takeaways

• 14‑day ECG monitoring cut primary endpoint to 1.9% vs 6.6% control
• No increase in permanent pacemaker rates despite earlier implantation timing
• New‑onset atrial fibrillation detected more often in monitored patients (8.9% vs 1.8%)
• Patients with widened QRS benefited most; monitoring eliminated events in this subgroup
• Study paves way for RCT targeting TAVI patients with baseline conduction disturbances

Pulse Analysis

Transcatheter aortic valve implantation (TAVI) has become the preferred therapy for high‑risk aortic stenosis, yet post‑procedure conduction disturbances remain a leading source of morbidity. Traditional follow‑up relies on brief in‑hospital telemetry, which may miss delayed arrhythmic events that develop as the valve settles or as the patient’s native conduction system ages. Expanding surveillance to the outpatient setting with wearable, wire‑free monitors offers clinicians a longer window to capture clinically silent episodes, aligning with broader trends toward remote cardiac monitoring and value‑based care.

The RECORD registry’s observational cohort of 1,217 patients provides compelling evidence that a 14‑day ambulatory ECG patch can halve the rate of serious cardiovascular outcomes. The monitored group experienced a 1.9% incidence of the composite endpoint versus 6.6% in controls, driven primarily by reductions in sudden cardiac death and arrhythmic syncope. Importantly, the strategy did not inflate permanent pacemaker implantation, and when devices were placed they occurred earlier, suggesting timely intervention without overtreatment. The higher detection of new‑onset atrial fibrillation (8.9% vs 1.8%) also hints at secondary stroke‑prevention benefits, although stroke rates themselves were unchanged at one year.

These findings have set the stage for a randomized controlled trial that will focus on patients with pre‑existing conduction abnormalities—a subgroup that showed the greatest risk reduction in the subanalysis. If the trial confirms the observational data, professional societies may broaden post‑TAVI monitoring recommendations beyond the current narrow indication for new conduction blocks. Such a shift could improve patient safety, reduce downstream hospitalizations, and do so with a relatively low‑cost technology, making it an attractive addition to the evolving TAVI care pathway.